價(jià)格 | ¥182 | ¥369 | ¥593 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱:烏苯美司 | 英文名稱:Bestatin |
CAS:58970-76-6 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.63% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T1257 |
名稱 | Bestatin |
描述 | Bestatin (Ubenimex) competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Ubenimex is a microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage, and bone marrow stem cell as well as stimulates the release of interleukin-1 and -2, thus further enhances its antitumor activity. |
細(xì)胞實(shí)驗(yàn) | Growing cells (1×106 to 2×106 cells/mL) are diluted to 1.0×103 cells/mL and transferred (3 mL) into a well in a 12-well multiwell plate (2.5-cm diameter/well). Cells are treated with 0, 10, 50, 100, 300, or 600 μM Bestatin and allowed to grow at 21°C shaking at 180 rpm for 48 h. A hemocytometer is used to measure cell density after 0, 24, and 48 h. |
激酶實(shí)驗(yàn) | Cells are harvested, washed, and lysed in NP-40 lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5% NP-40). Total cell protein is quantified using the Bradford assay and 1-mg/mL protein aliquots are made. Ten microliters of total cell protein is mixed with 290 μL of substrate solution (0.1 mg/mL dithiothreitol [DTT], 0.1 mg/mL albumin, and 1 mM alanine-β-naphthylamide). Fluorometric measurements (340 nm excitation, 400 nm emission) are made after 15 and 30 min. The slope of the line between the 15- and 30-min measurements is used to represent aminopeptidase activity. Total cell protein is preincubated with bestatin, amastatin, puromycin, EDTA, and/or ZnCl2 for 20 min before the fluorometric aminopeptidase assay. |
體外活性 | 在B16-BL6黑色素瘤細(xì)胞荷瘤的小鼠背部側(cè)中,Bestatin使既定原發(fā)性腫瘤塊血管的數(shù)量下降.在小鼠背部氣囊測(cè)定中,Bestatin顯著抑制黑色素瘤細(xì)胞誘導(dǎo)的血管生成. 在EGDA大鼠中,Bestatin可降低EAC的發(fā)病率(57.7%降至26.1%).在EGDA大鼠的食管組織中,Bestatin對(duì)白三烯B4生物合成的抑制具有明顯的統(tǒng)計(jì)學(xué)意義. |
體內(nèi)活性 | Bestatin對(duì)SN12M細(xì)胞侵入重組基底膜(基質(zhì)膠)具有濃度依賴性的抑制作用。在非腫瘤條件培養(yǎng)基中,其還可濃度依賴性抑制腫瘤細(xì)胞IV型膠原退化。在U937細(xì)胞中,烏苯美司可使caspase-3的活性增強(qiáng)并誘導(dǎo)DNA梯和DNA片段化。在SN12M Bestatin抑制氨基肽酶底物的水解活性。Bestatin對(duì)人臍靜脈內(nèi)皮細(xì)胞中的管狀形成具有抑制作用。通過(guò)固定在細(xì)胞表面的亮氨酸氨肽酶,Bestatin直接刺激淋巴細(xì)胞(和單核細(xì)胞),而間接刺激則是通過(guò)氨基肽酶乙抑制吞噬作用激素的分解代謝發(fā)揮。 |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | 1eq. NaOH : 15.4 mg/mL (50 mM) |
關(guān)鍵字 | Aminopeptidase | Bacterial | Inhibitor | Antibiotic | Bestatin | inhibit |
相關(guān)產(chǎn)品 | Crystal Violet | Dehydroacetic acid sodium | G-418 disulfate | Doxycycline | Methyl anthranilate | Neomycin sulfate | Metronidazole | Dimethyl sulfoxide | EDTA copper(II) disodium salt | Ampicillin sodium | Sulfamethoxazole sodium | Kanamycin sulfate |
相關(guān)庫(kù) | 抑制劑庫(kù) | 微生物天然產(chǎn)物庫(kù) | 抗癌上市藥物庫(kù) | 抗癌活性化合物庫(kù) | 抗癌天然產(chǎn)物庫(kù) | 天然產(chǎn)物庫(kù) | 抗病毒庫(kù) | 藥物功能重定位化合物庫(kù) | 高通量篩選天然產(chǎn)物庫(kù) | 抗感染天然產(chǎn)物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.2651萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營(yíng)模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥200 |
VIP6年
|
上??道噬锟萍加邢薰?/div>
|
2024-12-26 | |
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2024-12-26 | |
詢價(jià) |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2024-12-26 | |
詢價(jià) |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2024-12-26 | |
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-12-26 | |
詢價(jià) |
VIP3年
|
上海嘉定區(qū)澄瀏公路52號(hào)
|
2024-12-25 | |
詢價(jià) |
中國(guó)食品藥品檢定研究院
|
2024-12-25 | ||
詢價(jià) |
VIP7年
|
麻城市進(jìn)鑫生物科技有限公司
|
2024-12-24 | |
¥1452 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-12-20 | |
詢價(jià) |
VIP14年
|
成都傲飛生物化學(xué)品有限責(zé)任公司
|
2024-12-11 |